ErtapenemAcquired drug resistance following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1909卷 / 1期

关键词：

D O I：

10.1007/s40278-022-16532-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：245 / 245

相关论文

共 50 条

[1] LarotrectinibAcquired drug resistance and liver toxicity following off-label use: case report
[J]. Reactions Weekly, 2023, 1978 (1) : 221 - 221
[2] AntineoplasticsTreatment failure, drug resistance and off-label use: case report
[J]. Reactions Weekly, 2022, 1931 (1) : 85 - 85
[3] Cetuximab/encorafenibDevelopment of drug resistance and off-label use: case report
[J]. Reactions Weekly, 2022, 1894 (1) : 103 - 103
[4] Alectinib/crizotinibAcquired drug resistance and off-label use: case report
[J]. Reactions Weekly, 2021, 1856 (1) : 23 - 23
[5] AntifungalsMulti-drug resistance, and transient rash following off-label use: case report
[J]. Reactions Weekly, 2023, 1945 (1) : 66 - 66
[6] Ceftolozane/tazobactamTreatment failure secondary to drug resistance following an off-label use: case report
[J]. Reactions Weekly, 2018, 1712 (1) : 157 - 157
[7] AfatinibVarious toxicities and drug resistance following off-label treatment: case report
[J]. Reactions Weekly, 2021, 1880 (1) : 22 - 22
[8] RituximabPancytopenia following off-label use: case report
[J]. Reactions Weekly, 2020, 1807 (1) : 176 - 176
[9] FavipiravirNephrotoxicity following off-label use: case report
[J]. Reactions Weekly, 2022, 1929 (1) : 283 - 283
[10] DexamethasoneHyperglycaemia following off-label use: case report
[J]. Reactions Weekly, 2022, 1896 (1) : 173 - 173

← 1 2 3 4 5 →